SAN DIEGO, CA and VANCOUVER, Sept. 14, 2012 /CNW/ - Sophiris Bio Inc.
(TSX: SHS) today announced that Alexander Casdin has resigned as the
CFO of Sophiris Bio. "Alex has accomplished the goals established when
he joined. He was a valuable member of our management team and has
done an excellent job establishing the financial operations of Sophiris
and positioning the company for success. Given his accomplishments and
the company's strong position, he now intends to pursue his future
interests in the life science industry and we wish him well," said
Randall Woods, CEO of Sophiris Bio.
Sophiris is currently evaluating the structure of the Company's finance
department and in the interim Peter Slover, Head of Finance and
Principal Accounting Officer, will assume Mr. Casdin's duties. Mr.
Slover was the Vice President, Finance and Operations at Anadys
Pharmaceuticals, Inc. prior to joining Sophiris in April 2011. Mr.
Casdin has made himself available to us should we need his counsel on
For additional information and other publicly filed documents relating
to Sophiris, please see the Company filings at www.sedar.com.
About Sophiris Bio:
Sophiris Bio Inc. is a urology company developing a late-stage, highly
targeted treatment for benign prostatic hyperplasia (BPH or enlarged
prostate), an unsatisfied market with large potential demand. PRX302,
the company's lead candidate for BPH, is designed to be as efficacious
as pharmaceuticals, less invasive than the surgical interventions, and
without the sexual side effects seen with existing treatments. Sophiris
is planning to begin a pivotal trial by the end of 2012. Sophiris is
advised by world-leading urologists, backed by experienced investors,
and led by a team that has achieved more than twenty drug approvals
including several drugs with annual sales in excess of $1billion. For
more information, please visit www.sophirisbio.com.
Certain statements included in this press release may be considered
forward-looking, including statements about the potential for PRX302.
Such statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by such
statements, and therefore these statements should not be read as
guarantees of future performance or results. All forward-looking
statements are based on Sophiris Bio's' current beliefs as well as
assumptions made by and information currently available to Sophiris Bio
and relate to, among other things, anticipated financial performance,
business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties inherent in late stage drug
development and risks relating to obtaining FDA and other regulatory
approvals as well as risks identified by Sophiris Bio in its public
securities filings; actual events may differ materially from current
expectations. Sophiris Bio disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
SOURCE: Sophiris Bio, Inc.
For further information:
The Trout Group